Time point | Group 1 and 2 pooled, YF− (n = 116) | Group 3, YF− (n = 108) | ||||
---|---|---|---|---|---|---|
n | GMT (95% CI) | Seropositive, % (95% CI) | n | GMT (95% CI) | Seropositive, % (95% CI) | |
Serotype 1 | ||||||
Baseline | 116 | 5.19 (4.87–5.53) | 1.7 (0.2–6.1) | 108 | 5.00 (NC) | 0 (0.0–3.4) |
Post-dose 1 | 116 | 8.71 (7.04–10.8) | 23.3 (15.9–32.0) | 108 | 7.68 (6.46–9.14) | 20.4 (13.2–29.2) |
Serotype 2 | ||||||
Baseline | 116 | 5.06 (4.94–5.19) | 0.9 (0.0–4.7) | 108 | 5.06 (4.94–5.20) | 0.9 (0.0–5.1) |
Post-dose 1 | 116 | 18.8 (13.9–25.3) | 46.6 (37.2–56.0) | 108 | 10.8 (8.63–13.4) | 35.2 (26.2–45.0) |
Serotype 3 | ||||||
Baseline | 116 | 5.21 (4.97–5.47) | 2.6 (0.5–7.4) | 108 | 5.28 (4.90–5.69) | 2.8 (0.6–7.9) |
Post-dose 1 | 114 | 28.5 (20.4–39.7) | 57.9 (48.3–67.1) | 108 | 8.88 (7.23–10.9) | 25.0 (17.2–34.3) |
Serotype 4 | ||||||
Baseline | 116 | 5.43 (4.99–5.92) | 3.4 (0.9–8.6) | 108 | 5.26 (4.90–5.65) | 1.9 (0.2–6.5) |
Post-dose 1 | 114 | 229 (139–378) | 74.6 (65.6–82.3) | 107 | 22.6 (15.9–32.3) | 48.6 (38.8–58.5) |